Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/170589
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sánchez-López, E. (Elena) | - |
dc.contributor.author | Paús Frutos, Anna | - |
dc.contributor.author | Pérez-Pomeda, Ignacio | - |
dc.contributor.author | Calpena Campmany, Ana Cristina | - |
dc.contributor.author | Haro, Isabel | - |
dc.contributor.author | Gomara, Maria José | - |
dc.date.accessioned | 2020-09-14T09:32:43Z | - |
dc.date.available | 2020-09-14T09:32:43Z | - |
dc.date.issued | 2020-05-31 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | http://hdl.handle.net/2445/170589 | - |
dc.description.abstract | The effective use of fusion inhibitor peptides against cervical and colorectal infections requires the development of sustained release formulations. In this work we comparatively study two different formulations based on polymeric nanoparticles and lipid vesicles to propose a suitable delivery nanosystem for releasing an HIV-1 fusion inhibitor peptide in vaginal mucosa. Polymeric nanoparticles of poly-d,l-lactic-co-glycolic acid (PLGA) and lipid large unilamellar vesicles loaded with the inhibitor peptide were prepared. Both formulations showed average sizes and polydispersity index values corresponding to monodisperse systems appropriate for vaginal permeation. High entrapment efficiency of the inhibitor peptide was achieved in lipid vesicles, which was probably due to the peptide's hydrophobic nature. In addition, both nanocarriers remained stable after two weeks stored at 4 °C. While PLGA nanoparticles (NPs) did not show any delay in peptide release, lipid vesicles demonstrated favorably prolonged release of the peptide. Lipid vesicles were shown to improve the retention of the peptide on ex vivo vaginal tissue in a concentration sufficient to exert its pharmacological effect. Thus, the small size of lipid vesicles, their lipid-based composition as well as their ability to enhance peptide penetration on vaginal tissue led us to consider this formulation as a better nanosystem than polymeric nanoparticles for the sustained delivery of the HIV-1 fusion inhibitor peptide in vaginal tissues. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics12060502 | - |
dc.relation.ispartof | Pharmaceutics, 2020, vol. 12, num. 6, p. 502 | - |
dc.relation.uri | https://doi.org/10.3390/pharmaceutics12060502 | - |
dc.rights | cc-by (c) Sánchez-López, E. (Elena) et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
dc.subject.classification | Lípids | - |
dc.subject.classification | Sistemes d'alliberament de medicaments | - |
dc.subject.classification | Nanopartícules | - |
dc.subject.other | Lipids | - |
dc.subject.other | Drug delivery systems | - |
dc.subject.other | Nanoparticles | - |
dc.title | Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 702982 | - |
dc.date.updated | 2020-09-14T09:32:43Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32486415 | - |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
702982.pdf | 908.19 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License